ODYSSEUS DATA SERVICES SRO

Their core work

Odysseus Data Services is a Czech health data technology company specializing in the conversion, standardization, and federated analysis of real-world clinical data. Their core work revolves around the OMOP Common Data Model (CDM) and the OHDSI open-source analytics ecosystem — they help healthcare institutions transform heterogeneous patient data into a standardized format that can be analyzed across multiple sites without sharing raw data. In EHDEN, one of Europe's largest federated health data networks, they contributed directly to building the technical infrastructure for federated queries and prediction model deployment across hospital networks. More recently they have extended into the regulatory and ethical layer, addressing how clinical trial data can be responsibly reused under GDPR and evolving EU data governance frameworks.

What they specialise in

How they've shifted over time

From 2018, Odysseus focused on the technical plumbing of health data — converting raw hospital records into OMOP CDM, building federated query infrastructure, and enabling open-source analytics through OHDSI tools. This was fundamentally an engineering and data standardization role. By their second project (2022), the focus had shifted upstream toward governance: how clinical data, once standardized, can legally and ethically be reused for research under GDPR, and how to involve patients as active participants in that process. The trajectory shows a company maturing from pure technical implementation into a position that bridges data engineering with regulatory and ethical compliance — a combination that is increasingly rare and valuable in European health data projects.

Odysseus is moving toward the intersection of health data engineering and EU data governance — positioning themselves as a company that can handle both the technical conversion of clinical data and the legal/ethical frameworks required to use it, which aligns directly with the European Health Data Space regulation coming into force.

How they like to work

Odysseus participates exclusively as a consortium partner — they have never led an H2020 project — which suggests they operate as a specialist technical contributor rather than a project orchestrator. Both their projects are large RIA consortia (EHDEN had dozens of partners across Europe), indicating they are comfortable working within complex multi-partner environments and contributing a well-defined technical component. This makes them a predictable, low-coordination-overhead partner for consortium builders who need a specific OMOP/OHDSI capability without needing to manage a lead organization.

Across two projects, Odysseus has accumulated 48 unique consortium partners spanning 18 countries — a remarkably broad network for an SME with only two projects, reflecting the large-scale consortia (EHDEN alone involved dozens of hospitals, universities, and data companies across Europe). Their network is pan-European in character, with no obvious single-country concentration.

What sets them apart

Odysseus occupies a narrow but high-demand niche: they are one of relatively few private SMEs in Central Europe with hands-on experience in both OMOP CDM data conversion at scale and federated analytics using the OHDSI toolset, validated through participation in EHDEN — arguably the most prominent real-world evidence network project funded under H2020. For a consortium needing OMOP expertise without engaging a large consultancy or academic group, Odysseus offers practical delivery capability combined with the credibility of having worked in a flagship EU health data infrastructure project. Their emerging GDPR and data reuse expertise makes them increasingly relevant as the European Health Data Space creates new compliance requirements.

Highlights from their portfolio

• EHDEN
  One of H2020's flagship real-world evidence projects, building a federated network across hundreds of European hospital data sources standardized to OMOP CDM — Odysseus received the largest share of their total EU funding here (EUR 781,875).
• FACILITATE
  Addresses the legally complex problem of reusing clinical trial participant data under GDPR with a patient-centred approach — a frontier topic as EU health data regulation expands.